Integra LifeSciences (NASDAQ:IART) Releases FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.410-2.510 for the period, compared to the consensus earnings per share estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Integra LifeSciences Stock Performance

IART stock opened at $24.04 on Wednesday. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $44.69. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -265.97, a PEG ratio of 0.73 and a beta of 1.17. The business’s fifty day simple moving average is $23.71 and its two-hundred day simple moving average is $21.83. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. During the same quarter last year, the firm posted $0.89 EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. Analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Three research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $23.00.

Insiders Place Their Bets

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.